Company Overview and News

11
Nexeo Solutions downgraded to hold from buy at SunTrust RH

2018-09-19 marketwatch
Univar Inc. said Monday that it planned to acquire Nexeo Solutions Inc. for $2 billion in cash and stock, valuing the company at $11.65 a share. Nexeo shares closed at $10.01, and were halted early in the after-hours session ahead of the announcement. Nexeo, which distributes chemicals and plastics, was previously acquired for about $1.6 billion in 2016 by a company run by Wilbur Ross, who has since become the U.
NXEOW ADAP UNVR SBLKL FNFV KHC NXEO BIP NXEOU SBLK FNF

 
FNF / Fidelity National Financial, Inc. null

2018-09-13 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$Q(# @;V)J#3P\+TQI;F5A
FNF

 
FNF / Fidelity National Financial, Inc. null

2018-09-13 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S,U [email protected] Q,2]%(#(X,C,[email protected],B]4(#,S,[email protected]@6R [email protected],30X73X^#65N M9&]B:@[email protected](" @(" @(" @(" @(" @(" @#0HQ-B P(&]B:@T\/"]$96-O9&50 M87)M7!E+UA2968O5ULQ(#(@,5T^/G-T
FNF

 
FNF / Fidelity National Financial, Inc. null

2018-09-13 sec.gov
Fidelity National Financial, Inc. 601 Riverside Avenue Jacksonville, FL 32
FNF

7
5 Top-Ranked Financial Stocks to Buy in Spooky September

2018-09-10 zacks
Of late, the finance sector has been putting up an impressive performance, with some monthly volatility. The United States’ economic health, on which this sector is largely dependent, has been displaying steady improvement with increasing real GDP numbers, declining unemployment rate, improving consumer spending and stabilizing housing market. Further, the likelihood of another rate hike in the near future continues to dominate the headlines.
BRK.A ALL LAZ MET KO WTFC FNF

 
Paranoid Silicon Valley magnates pour millions into NZ doomsday bunkers

2018-09-05 nzherald.co.nz
In recent months, two 150-tonne survival bunkers journeyed by land and sea from a Texas warehouse to the shores of New Zealand, where they're buried 11 feet underground.
FNFV FNF

 
FNF / Fidelity National Financial, Inc. 425 (Prospectus)

2018-08-22 sec.gov
Filed by Fidelity National Financial, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule&
FNF

 
FNF / Fidelity National Financial, Inc. 425 (Prospectus)

2018-08-22 sec.gov
Filed by Fidelity National Financial, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule&
FNF

5
Fidelity National (FNF) Prices Senior Notes Worth $450M

2018-08-13 zacks
Fidelity National Financial, Inc. (FNF - Free Report) has announced the pricing of $450 million aggregate principal amount of Senior Notes. The notes carry an interest rate of 4.50% with maturity scheduled on Aug 15, 2028. Following the release of this news, the company gained 0.3% in the last trading session. The company priced the senior notes at 99.252%, which will yield 4.594% on maturity. These notes will pay interest on a semi-annual basis – on February and August, 2019.
FOX STC FNFV PGR LMHA NMIH LMHB FOXA Y FNF LM

 
FNF / Fidelity National Financial, Inc. 10-Q (Quarterly Report)

2018-08-06 sec.gov
Document Table of Contents <
FNF

 
FNF / Fidelity National Financial, Inc. 424B3 (Prospectus)

2018-08-01 sec.gov
Use these links to rapidly review the document Table of Contents INDEX TO FNF'S FINANCIAL STATEMENTS TABLE OF CONTENTS
FNF

8
Affiliated Managers (AMG) Surges: Stock Moves 5.1% Higher

2018-07-31 zacks
Affiliated Managers Group, Inc. (AMG - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $147.23 to $152.43 in the past one month time frame.
CWH MGR FNFV AMG FNF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to FNF / Fidelity National Financial, Inc. on message board site Silicon Investor.

Fidelity National Financial, Inc. - FNF Fidelity National Financial, Inc. - FNF Fidelity National Financial, Inc. - FNF BBY WMT FNF STC AVEI UEIC CMED FRX KSU Articles from Net BBY WMT FNF STC AVEI UEIC CMED FRX KSU Articles from Net BBY WMT FNF STC AVEI UEIC CMED FRX KSU Articles from Net
CUSIP: 31620R303